Antithrombotic
therapy is a cornerstone of
acute ischemic stroke (AIS) management and secondary
stroke prevention. Since the first version of the Korean Clinical Practice Guideline (CPG) for
stroke was issued in 2009, significant progress has been made in antithrombotic
therapy for patients with AIS, including dual antiplatelet
therapy in acute minor
ischemic stroke or high-risk transient
ischemic stroke and early oral anticoagulation in AIS with
atrial fibrillation. The evidence is widely accepted by
stroke experts and has changed clinical practice. Accordingly, the CPG Committee of the Korean
Stroke Society (KSS) decided to update the Korean
Stroke CPG for antithrombotic
therapy for AIS. The writing members of the CPG committee of the KSS reviewed recent evidence, including clinical trials and relevant literature, and revised recommendations. A total of 35 experts were invited from the KSS to reach a consensus on the revised recommendations. The current guideline update aims to assist healthcare providers in making well-informed decisions and improving the quality of
acute stroke care. However, the ultimate treatment decision should be made using a holistic approach, considering the specific medical conditions of individual patients.